Real world experience with 259 dediff. liposarcomas. Primary surgery in 79% of cases, 11% having inoperable disease and 10% synchr. metastasis. Local relapse in 44.0% of patients, 31% develop metachronous metastasis. Read our series Casier et al. DOI: 10.1186/s12885-025-13813-w .

Survival outcome in dedifferentiated liposarcoma. Read DOI: 10.1186/s12885-025-13813-w . Median overall survival for all patients from diagnosis to death 70.5 mo, 10.9 mo for inoperable patients, 28.4 mo for local relapse and 9.4 mo only for patients with metastatic disease.

98 patients with advanced dediff. liposarcoma treated with doxo (52.0%), doxo/ifo (12%) or experimental therapy (18.4%). No difference in median overall survival comparing doxo and doxo/ifo as 1st line systemic treatment (11.9 vs 8.7 mo, p=0.16): Casier et al BMC Cancer 2025

#CTOS2025 registration and abstract submission system is open! 🎉Don't miss the biggest #sarcoma meeting and unique celebration of CTOS's 30th anniversary! 🗓️ We are waiting for your abstracts until Jun 20th! More details on the meeting website ⏩ ctos.org/Meeting/2025An…

Save the date: FORTRESS 2026 in Leuven Belgium)! Follow further announcements via kuleuven.be/fortress

Strong signals on the critical importance of diversity and inclusion in science and maintained public funding of medical research by multiple distinguished speakers during the AACR opening ceremony

Successful FORTRESS meeting series is now resulting in first scientific publications, e.g. a guideline paper on the establishment of patient-derived 3D in vitro models of sarcomas. Congratulations to the very active working group members. Read De Cock L et al. in Neoplasia 2025

Invite to FORTRESS translational research workshop (Leuven, Feb. 2026) mailed around earlier this week. Don’t forget to register NOW. By invitation only. Attendance limited to 130 participants and only one guest can win the famous trophy! kuleuven.be/fortress/locat…

Interested in Langerhans, Erdheim-Chester, Rosai-Dorfman and other super rare histiocytic neoplasms? Good summary of real-world experience in the Low Countries with targeted treatments in Kemps et al. doi: 10.1016/j.bneo.2024.100023

Sanofi acquired Blueprint Medicines Corporation, the developer of avapritinib, elenestinib and BLU-808. Important nieuws for GIST and systemic mastocytosis experts.

Can hardly recall that I ever had 4 ongoing, actively recruiting, sarcoma-specific first in human Phase 1 trials at the same time. ADCs, bifunctional antibodies and novel kinase inhibitors - what a privilege, really can’t complain… Send your patients for these exclusive trials!

The European Medicines Agency’s Committee for Medicinal Products has recommended granting marketing authorization for nirogacestat for the treatment of adults with progressing desmoid tumors. See also c.peerview.com/live/programs/…

Ascleipieon in Kos (Greece) - the birthplace of modern medicine, 200 years bc

CTOS is launching a Young Investigators Group for the next generation of sarcomologists. Get involved!

FORTRESS 2026 in Leuven already now fully booked! We apologize to those who cannot join anymore - we try to keep the Workshop small and interactive, in the best interest of our guests

Leuven (Belgium) selected to be the European Capital of Culture in 2030. Good choice - come and visit us!

Yet another succesful PhD thesis from the Lab. of Exp. Oncology in Leuven: Chao-Chi (Ally) Wang presented her preclinical evaluation of novel antibody-drug conjugates targeting uPARAP/Endo180 in sarcoma xenografts, providing the rationale for the ongoing Phase 1 trial NCT06797999

I wish all spider plots from sarcoma trials would look like the one from the recent update of the DeFi trial leading to regulatory approval of nirogacestat in US and Europe for our patients with desmoid fibromatosis. doi.org/10.1200/JCO-25…

Death receptor 5 agonist ozekibart (INBRX-109) doubles PFS in pts with advanced or metastatic, IDH-mutated or -wildtype chondrosarcoma when compared to placebo, and delays deterioration in pain and other PROs. Read INHIBRx press release and Subbiah et al. Clin Cancer Res 2023